Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


David Scheinberg joins Galena's SAB

This article was originally published in Scrip

Executive Summary

Galena Biopharma, a biotech company developing targeted oncology treatments, has appointed Dr David Scheinberg to its scientific advisory board. Dr Scheinberg is Memorial Sloan-Kettering Cancer Center's Vincent Astor chair, chair of the Molecular Pharmacology and Chemistry Program in the Sloan-Kettering Institute, and chair of the Experimental Therapeutics and the Nanotechnology Centers at Memorial Sloan-Kettering. In addition, Dr Scheinberg is professor of medicine and pharmacology at Weill-Cornell Medical College and serves on the boards of Progenics and Contrafect, and the scientific advisory boards of Actinium Pharmaceuticals, Ensysce Biosciences and OncoPep.

You may also be interested in...

Almirall launches Constella in six European markets

Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.

Dermira raises $35m in series B

Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.

Clovis ups public offering to $240m

Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts